TABLE 3.
In vivo antibacterial activities of RWJ-54428, cefotaxime, and penicillin G in a mouse model of pneumonia caused by S. pneumoniae ATCC 6301a
| Compound | MIC (μg/ml) | Total doseb (mg/kg) | Mean ± SD log CFU in lungsc |
|---|---|---|---|
| No treatment | 0 | 7.1 ± 0.5 | |
| RWJ-54428 | 0.015 | 5 | 4.8 ± 0.5** |
| 10 | <2.0d** | ||
| 20 | <2.0d** | ||
| Cefotaxime | 0.015 | 5 | 6.3 ± 0.2* |
| 10 | 5.1 ± 0.7** | ||
| 20 | 2.7 ± 1.1** | ||
| Penicillin G | 0.06 | 5 | 7.0 ± 0.2 |
| 10 | 6.1 ± 0.4* | ||
| 20 | 3.2 ± 0.9** |
a
The challenge dose was 3.0 × 105 CFU/mouse.
b
Doses were administered at 24 and 30 h postinoculation.
c
The numbers of viable CFU in the lungs were counted 18 h after the last dose. The difference between the control group and each treated group was determined by using a Peritz F test (∗, P < 0.05; ∗∗, P < 0.01).
d
The limit of detection was 2.0 log CFU/lung.